Repligen (FRA:RGN) EV-to-Revenue : 15.66 (As of May. 21, 2024)

View and export this data going back to . Start your Free Trial

What is Repligen EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Repligen's enterprise value is €8,788.3 Mil. Repligen's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €561.3 Mil. Therefore, Repligen's EV-to-Revenue for today is 15.66.

The historical rank and industry rank for Repligen's EV-to-Revenue or its related term are showing as below:

FRA:RGN' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.95 Med: 12.64 Max: 35.26
Current: 15.73

During the past 13 years, the highest EV-to-Revenue of Repligen was 35.26. The lowest was 2.95. And the median was 12.64.

FRA:RGN's EV-to-Revenue is ranked worse than
87.35% of 830 companies
in the Medical Devices & Instruments industry
Industry Median: 3.265 vs FRA:RGN: 15.73

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-21), Repligen's stock price is €156.60. Repligen's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €9.93. Therefore, Repligen's PS Ratio for today is 15.77.

Repligen EV-to-Revenue Historical Data

The historical data trend for Repligen's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Repligen EV-to-Revenue Chart

Repligen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

16.84

27.44

21.50

11.49

15.64

Repligen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial															11.79	10.56	12.93	15.64	16.84

Competitive Comparison of Repligen's EV-to-Revenue

For the Medical Instruments & Supplies subindustry, Repligen's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Repligen's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Repligen's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Repligen's EV-to-Revenue falls into.

Repligen EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Repligen's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	8788.256	/	561.264
	=	15.66

Repligen's current Enterprise Value is €8,788.3 Mil.
Repligen's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €561.3 Mil.

Repligen (FRA:RGN) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Repligen's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	156.60	/	9.929
	=	15.77

Repligen's share price for today is €156.60.
Repligen's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €9.93.

Repligen EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Repligen's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Repligen (FRA:RGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Repligen Corp (FRA:RGN) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

RGEN:USA RGN:Germany

Address

41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453

Website

https://www.repligen.com

Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.

Repligen (FRA:RGN) Headlines

No Headlines